ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

ACS Survey Finds Need for Cancer Education Among Hispanic Americans

August 2, 1985

Joseph Simone Accepts Chief Physician Job At Memorial Hospital, Succeeding DeVita

February 21, 1992

Chart of Core Grants

October 18, 1991

Antman Is President Elect; Minorities More Likely To Get Worse Care, IOM Finds

April 12, 2002

Danish Researchers Post Long-Awaited Aranesp Results–Ever So Discreetly.

February 16, 2007

Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival

December 28, 2012